Greater Specificity for Cerebrospinal Fluid P-tau231 over P-tau181 in the Differentiation of Healthy Controls from Alzheimer's Disease

Journal of Alzheimer's Disease

Volumn 49, Issue 1, 2015, Pages 93-100

  Spiegel, Jonathan ^a,b   Pirraglia, Elizabeth ^a   Osorio, Ricardo S ^a   Glodzik, Lidia ^a   Li, Yi ^a   Tsui, Wai ^a   Saint Louis, Leslie A ^c   Randall, Catherine ^a   Butler, Tracy ^a   Xu, Jinfeng ^a   Zinkowski, Raymond P ^d   Zetterberg, Henrik ^e   Fortea, Juan ^f   Fossati, Silvia ^a   Wisniewski, Thomas ^a   Davies, Peter ^g   Blennow, Kaj ^e   De Leon, Mony J ^a,h  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Wellington C Mepham High School   (United States)

^c Manhattan Diagnostic Radiology   (United States)

^d Pioneer BioSolutions   (United States)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^g FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^h NEW YORK UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; biomarkers; hyperphosphorylated tau; P tau181; P tau231

Indexed keywords

BIOLOGICAL MARKER; PHOSPHORYLATED TAU 181; PHOSPHORYLATED TAU 231; TAU PROTEIN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DSM-IV; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MEDICAL HISTORY; MINI MENTAL STATE EXAMINATION; NATIONAL HEALTH ORGANIZATION; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; CASE CONTROL STUDY; MIDDLE AGED; PHOSPHORYLATION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PHOSPHORYLATION; ROC CURVE; SENSITIVITY AND SPECIFICITY; TAU PROTEINS;

EID: 84948675164     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150167     Document Type: Article

References (31)

1. Iqbal K, Alonso AC, Chen S, Chohan MO, El-Akkad E, Gong CX, Khatoon S, Li B, Liu F, Rahman A (2005) Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 1739, 198-210.
2. Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ (2010) Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol 45, 30-40.
3. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT (2002) Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 103, 26-35.
4. Mitchell AJ (2009) CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: A meta-analysis of 51 studies. J Neurol Neurosurg Psychiatry 80, 966-975.
5. Buerger K, Alafuzoff I, Ewers M, Pirttila T, Zinkowski R, Hampel H (2007) No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 130, e82.
6. Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel SJ, DeBernardis J, Kerkman D, McCulloch C, Soininen H (2006) CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129, 3035-3041.
7. American Psychiatric Association and American Psychiatric Association Task Force on DSM-IV (1994) Diagnostic and Statistical Manual of Mental Disorders: DSM-IV.
8. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 34, 939-939.
9. Reisberg B, Ferris SH, de Leon MJ, Crook T (1982) The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 139, 1136-1139.
10. Folstein MF, Folstein SE, McHugh PR (1975) "Minimental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
11. Main BF, Jones PJ, MacGillivray RT, Banfield DK (1991) Apolipoprotein E genotyping using the polymerase chain reaction and allele-specific oligonucleotide primers. J Lipid Res 32, 183-187.
12. Hyman BT, Trojanowski JQ (1997) Editorial on consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 56, 1095-1097.
13. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E (2012) National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 8, 1-13.
14. Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, Parnetti L, Perret-Liaudet A, Shaw LM, Teunissen C (2012) Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 8, 65-73.
15. Kohnken R, Buerger K, Zinkowski R, Miller C, Kerkman D, DeBernardis J, Shen J, Moller H-J, Davies P, Hampel H (2000) Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett 287, 187-190.
16. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjoegren M, Andreasen N, Blennow K (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285, 49-52.
17. Radebaugh T, Khachaturian Z (1998) Consensus report of the working group on: Molecular and biochemical markers of Alzheimer's disease. Neurobiol Aging 19, 109-116.
18. McNemar Q (1947) Note on the sampling error of the difference between correlated proportions or percentages. Psychometrika 12, 153-157.
19. Mattsson N, Rosen E, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M (2012) Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology 78, 468-476.
20. Mulder C, Verwey NA, van der Flier WM, Bouwman FH, Kok A, van Elk EJ, Scheltens P, Blankenstein MA(2010) Amyloid ? (1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 56, 248-253.
21. Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkman D, Ishiguro K (2004) Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: A comparative cerebrospinal fluid study. Arch Gen Psychiatry 61, 95-102.
22. Regeniter A, Kuhle J, Baumann T, Sollberger M, Herdener M, Kunze U, Camuso MC, Monsch AU (2012) Biomarkers of dementia: Comparison of electrochemiluminescence results and reference ranges with conventional ELISA. Methods 56, 494-499.
23. Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pallson E, Jakobsson J, Herukka SK, Owenius R, Olsson B (2014) Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. JAMA Psychiatry 71, 1183-1191.
24. Buerger K, Teipel SJ, Zinkowski R, Sunderland T, Andreasen N, Blennow K, Ewers M, DeBernardis J, Shen Y, Kerkman D (2005) Increased levels of CSF phosphorylated tau in apolipoprotein E4 carriers with mild cognitive impairment. Neurosci Lett 391, 48-50.
25. Engelborghs S, Sleegers K, Cras P, Brouwers N, Serneels S, De Leenheir E, Martin JJ, Vanmechelen E, Van Broeckhoven C, De Deyn PP (2007) No association of CSF biomarkers with APOEe4, plaque and tangle burden in definite Alzheimer's disease. Brain 130, 2320-2326.
26. Braak H, Braak E (1985) On areas of transition between entorhinal allocortex and temporal isocortex in the human brain. Normal morphology and lamina-specific pathology in Alzheimer's disease. Acta Neuropathol 68, 325-332.
27. Hyman BT, Van Hoesen GW, Kromer LJ, Damasio AR(1986) Perforant pathway changes and the memory impairment of Alzheimer's disease. Ann Neurol 20, 472-481.
28. Braak H, Del Tredici K (2013) Amyloid ? may be released from non-junctional varicosities of axons generated from abnormal tau-containing brainstem nuclei in sporadic Alzheimer's disease: A hypothesis. Acta Neuropathol 126, 303-306.
29. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356.
30. Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD (2013) Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol 12, 207-216.
31. Fortea J, Vilaplana E, Alcolea D, Carmona-Iragui M, Sanchez-Saudinos M, Sala I, Anton-Aguirre S, Gonzalez S, Medrano S, Pegueroles J (2014) CSF ?-amyloid and phosphotau biomarker interactions on brain structure in preclinical AD. Ann Neurol 76, 223-230.